首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1736772

全球生物製藥發酵系統市場：市場規模（按產品、應用、最終用戶和地區分類）、未來預測

Global Biopharmaceutical Fermentation Systems Market Size By Product, By Applications, By End User, By Geographic Scope And Forecast

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球生物製藥發酵系統市場規模及預測

2024 年生物製藥發酵系統市場規模價值 126.4 億美元，預計到 2032 年將達到 198.5 億美元，在 2026-2032 年預測期內的複合年成長率為 5.80%。

人口老化加劇、全球慢性病流行以及人類服務消費的不斷成長，正推動人們對生物製藥的興趣。這有望在預計的時間內推動全球生物製藥發酵系統市場的擴張。《全球生物製藥發酵系統市場報告》對市場進行了全面的評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

定義全球生物製藥發酵系統市場

生物製藥發酵系統可以定義為在密閉容器或發酵槽中，在受控的通氣、攪拌、溫度和pH條件下培養微生物的過程。細菌是發酵過程的基礎。完全依賴微生物的原料藥藥物以發酵作為唯一的生產途徑。例如，真菌產生的抗生素和次級代謝物可作為抗癌和抗感染劑物，革蘭氏陰性細菌產生的脂質A可作為佐劑。這些有機分子可以透過多步驟合成，由其基本單元衍生而來。

然而，有機分子本質上非常複雜，可能包含掌性中心、大型特異性環、獨特的共軛雙鍵系統等結構。合成路線不僅需要大量開發，而且耗時且成本高於發酵方法。

全球生物製藥發酵系統市場概況

人口老化加劇、全球慢性病氾濫以及人類服務消費的上升，正推動人們對生物製藥的興趣。這很可能在預計的時間內推動全球生物製藥發酵系統市場的擴張。多家製藥公司正在積極制定富有想像力的天然藥物新計劃並開展創新工作，以滿足人們忽視的有益需求。例如，印度最大的開發和推廣公司、全球三大胰島素生物相似藥公司之一Biocon已透過畢赤酵母成熟技術推廣了RH-胰島素（重組人類胰島素）。這是推動全球生物製藥發酵系統市場成長的主要因素。

然而，缺乏對生物製藥發酵系統領域的認知和訓練有素的專業人員可能會阻礙整體市場的成長。此外，引入更先進的技術來升級生產，實現更大規模的生產單位，並提高產品品質正被視為一個有利可圖的機會。

經過驗證的市場研究利用原始資訊提煉現有數據，檢驗數據，並以此編製全面的市場研究報告。本研究報告包含對客戶感興趣的市場要素的定量和定性評估。全球生物製藥發酵系統市場主要分為幾個細分市場，可以提供有關市場最新趨勢的分類資料。

Increment within the aged population, surge within the pervasiveness of chronic illnesses over the globe and increase in human services consumption drive interest for biopharmaceuticals. This is most likely to aim to fuel the expansion of the global Biopharmaceutical Fermentation Systems Market during the estimated period. The Global Biopharmaceutical Fermentation Systems Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Biopharmaceutical Fermentation Systems Market Definition

Biopharmaceutical fermentation systems can be defined as the process of incubating microorganisms within an enclosed tank or a fermenter, under controlled conditions of aeration, agitation, temperature, and pH. Bacteria are used as the basis of fermentation processes. Chemical APIs that rely solely on microorganisms have fermentation as the only route to produce it. Some of the examples are, antibiotics or secondary metabolites made in fungi serving as anticancer or anti-infectious agents, or lipid A made in gram-negative bacteria serving as adjuvants. Through multi-steps synthesis, such organic molecules can be derived from their building blocks.

However, organic molecules are quite complex in nature, potentially encompassing structures such as chiral centers, large stereospecific rings, or unique conjugated double bond systems. Going down the synthetic route not only requires significant development but is time-consuming and involves higher costs than the fermentation option.

Global Biopharmaceutical Fermentation Systems Market Overview

Increment within the aged population, surge within the pervasiveness of chronic illnesses over the globe, and increase in human services consumption drive interest for biopharmaceuticals. This is most likely to aiming to fuel the expansion of the global Biopharmaceutical Fermentation Systems Market during the estimated period. A few pharmaceutical organizations are occupied with innovative work of imaginative new plans and natural medications to satisfy the neglected helpful needs. For instance, Biocon, India's biggest, development drove, completely incorporated biopharmaceutical organization which positions among top three biosimilar worldwide players for insulin, has popularized the RH-insulin (recombinant human insulin) through Pichia maturation innovation. This is the major factor that boosts the growth of the global Biopharmaceutical Fermentation Systems Market.

However, lack of awareness and trained professionals in the field for biopharmaceutical fermentation systems might hamper the overall growth of the market. Moreover, introducing more advanced technologies to upgrade production, allow massive production units, and improve product quality approaches as profitable opportunities.

Verified Market Research narrows down the available data using primary sources to validate the data and use it in compiling a full-fledged market research study. The report contains a quantitative and qualitative estimation of market elements which interests the client. The "Global Biopharmaceutical Fermentation Systems Market" is mainly bifurcated into sub-segments which can provide a classified data regarding latest trends in the market.

Global Biopharmaceutical Fermentation Systems Market: Segmentation Analysis

The Global Biopharmaceutical Fermentation Systems Market is Segmented on the basis of Product, Applications, End User, And Geography.

Biopharmaceutical Fermentation Systems Market, By Product

Upstream Products
Bioreactors/Fermenters
Bioprocess Analyzers
Process Monitoring Systems
Others
Downstream Products
Filtration & Separation
Chromatography
Consumables & Accessories
Others
On the basis of product, the market is divided into 2 categories. The Upstream Process Product further studied across Bioreactors/Fermenters, Bioprocess Analyzers, Process Monitoring Systems and others. The Downstream Process Product further studied across Filtration and Separation Instruments, Chromatography Systems, Consumables and Accessories.

Biopharmaceutical Fermentation Systems Market, By Applications

Antibiotics
Recombinant Proteins
Probiotics
Others
On the basis of application, Biopharmaceutical Fermentation Systems market is divided into categories as mentioned above. Out of these, the recombinant proteins segment holds a major market share. High reliance on microbial systems for recombinant protein production contributed toward the leading share of the segment

Biopharmaceutical Fermentation Systems Market, By End User

Biopharmaceutical Companies
Contract Research Organizations
Academic Research Institutes
Food Industry
Others

Based on End User, the Biopharmaceutical Fermentation System Market studied across Biopharmaceutical Companies, Contract Research Organizations, Academic Research Institutes, Food Industry and others.

Biopharmaceutical Fermentation Systems Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, the Global Biopharmaceutical Fermentation Systems Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The global biopharmaceutical fermentation systems market is dominated by North America and Europe. This is due to the development of latest pharmaceutical companies and improving healthcare sector in U.S. and U.K. This can be the explanation that these regions are dominating the regional front of worldwide biopharmaceutical fermentation systems market from 2021 to 2028.

Key Players

The "Global Biopharmaceutical Fermentation Systems Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as GE Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius Stedim Biotech, Merck KGaA, Eppendorf AG, F. Hoffmann-La Roche Ltd., Nova Biomedicals, Lonza, Becton, Dickinson and Company.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

1 INTRODUCTION OF GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities

5 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY PRODUCT

5.1 Overview
5.2 Upstream Products
- 5.2.1 Bioreactors/Fermenters
- 5.2.2 Bioprocess Analyzers
- 5.2.3 Process Monitoring Systems
- 5.2.4 Others
5.3 Downstream Products
- 5.3.1 Filtration & Separation
- 5.3.2 Chromatography
- 5.3.3 Consumables & Accessories
- 5.3.4 Others

6 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY APPLICATIONS

6.1 Overview
6.2 Antibiotics
6.3 Recombinant Proteins
6.4 Probiotics
6.5 Others

7 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY END USER

7.1 Overview
7.2 Biopharmaceutical Companies
7.3 Contract Research Organizations
7.4 Academic Research Institutes
7.5 Food Industry
7.6 Others

8 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Middle East & Africa
- 8.5.2 Latin America

9 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 GE Healthcare
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Thermo Fisher Scientific Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Danaher Corporation
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Sartorius Stedim Biotech
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Merck KGaA
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Eppendorf AG
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 F. Hoffmann-La Roche Ltd.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Nova Biomedicals
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Lonza
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Becton, Dickinson and Company
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments